NEWRON PHARMACEUT. EO-20 Total Liabilities
NEWRON PHARMACEUT. EO-20 total liabilities. Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has total liabilities worth €51.19 Million EUR (≈ $59.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NEWRON PHARMACEUT. EO-20 (NP5) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NEWRON PHARMACEUT. EO-20 (2021–2025)
Total liabilities of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. This chart illustrates how NEWRON PHARMACEUT. EO-20's total liabilities have evolved over time, based on quarterly financial data.
NEWRON PHARMACEUT. EO-20 Competitors by Total Liabilities
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baoding Dongli Machinery Co.Ltd.
SHE:301298
|
China | CN¥290.11 Million |
|
Kaltura Inc
NASDAQ:KLTR
|
USA | $167.13 Million |
|
Dong-A St
KO:170900
|
Korea | ₩740.40 Billion |
|
Odfjell B
OL:ODFB
|
Norway | Nkr1.20 Billion |
|
Aurelius Technologies Bhd
KLSE:5302
|
Malaysia | RM179.97 Million |
|
Cint Group AB
ST:CINT
|
Sweden | Skr145.95 Million |
|
Gunung Raja Paksi
JK:GGRP
|
Indonesia | Rp214.41 Million |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
USA | $2.04 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down NEWRON PHARMACEUT. EO-20's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NP5 asset base.
Liquidity & Leverage Metrics
NEWRON PHARMACEUT. EO-20 Total Liabilities Ratios Explained
NEWRON PHARMACEUT. EO-20 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NEWRON PHARMACEUT. EO-20's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NEWRON PHARMACEUT. EO-20 (2021–2025)
The table below shows the annual total liabilities of NEWRON PHARMACEUT. EO-20 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €51.19 Million ≈ $59.85 Million |
-18.03% |
| 2024-12-31 | €62.45 Million ≈ $73.01 Million |
+11.97% |
| 2023-12-31 | €55.77 Million ≈ $65.21 Million |
+8.88% |
| 2022-12-31 | €51.23 Million ≈ $59.89 Million |
+8.12% |
| 2021-12-31 | €47.38 Million ≈ $55.39 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more